Had a gut microbiome signature associated with adenomatous polyps in Jona's research. Age-group findings closely aligned with published colonoscopy polyp prevalence data.
¹ Kosinski, L. R., Grady, L., Robert, E., Yoo, C., & Lieberman, D. A. (2026). Use of AI enhanced shotgun metagenomics as a tool to select patients under 45 for colon cancer screening.
Gastroenterology, 170(6), S-267–S-268. https://doi.org/10.1016/S0016-5085(26)00973-X
Lawrence Kosinski, MD, MBA
Chief Medical Officer, Jona
Gastroenterologist with 35 years of clinical experience and member of the American Gastroenterological Association Governing Board.
Colorectal cancer in adults under 50 accounts for 14% of new CRC cases. Routine screening begins at 45 for average-risk patients, leaving younger adults without a standard age-based screening pathway.
Many colorectal cancers develop from adenomatous polyps over time. Microbiome signatures associated with these lesions may provide additional information for clinical risk assessment, but are not diagnostic.
In adults under 40, 16.7% had a polyp-associated microbiome signature, compared with 13% polyp prevalence in colonoscopy data. The findings suggest potential utility for future risk stratification.
01
02
03
04
05
Jona goes beyond a narrow pathogen panel like most other tests. Unlike basic PCR methods, Jona uses deep shotgun metagenomic sequencing to identify, down to the strain level, all the bacteria, fungi, viruses, and other organisms in your patient's sample — usually leading to 10–20x more organisms detected than other tests.
Most available screening tools detect cancer or cancer signals already in the bloodstream. Jona's Clinical Gut Microbiome Analysis uses deep shotgun metagenomic sequencing to identify associations between your patients' microbiome and polyp-associated signatures — in patients of any age, with no invasive procedure required. Jona does not diagnose, treat, or prescribe.
Jona is available for patients of all ages — making it particularly valuable for patients under 45 who fall outside current screening age guidelines but whose microbiome may show associations worth evaluating.
Jona AI helps you interpret findings by identifying microbiome associations to conditions and symptoms based on 220K+ peer-reviewed studies. Using Digital Twin analysis, Jona simulates what actions your patient can take to improve their microbiome signatures — bringing the full breadth of microbiome science to your fingertips and saving you time.
Jona's Digital Twin models how dietary, lifestyle, and probiotic interventions may shift the microbiome — providing insight into potential outcomes before interventions are implemented.
Yes — Jona is HSA/FSA eligible with no Letter of Medical Necessity required. That means patients can access Jona instantly using their existing HSA or FSA funds — no extra steps, no delays, and no additional paperwork for your team.
Sign up at jona.health to access your dedicated practitioner portal. From there you can order tests in bulk, ship directly to patients, or share a patient-pay link — and access clinical education resources and interpretation support whenever you need them. Contact us at practices@jona.health to schedule a complimentary demo.
